It would be wrong for the research-based sector to go into the HTA review with a one-dimensional view of its own objectives grounded on the simple belief the government wants to deliver faster-reimbursed access to new therapeutic technologies. …
Starting in the right place means an honest assessment of the risks
September 12, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 1 August
August 1, 2025 - - Podcast -
Trump administration takes another step in 'Most Favored Nation' push
August 1, 2025 - - Latest News -
Novartis backs the launch of a new cardiovascular disease program
August 1, 2025 - - Latest News -
Study reveals growing benefit of Lilly therapy for early symptomatic Alzheimer’s disease
August 1, 2025 - - Latest News -
New pharmacy-focused partnership marks the launch of two first-to-market biosimilars
August 1, 2025 - - Latest News -
Arrotex expands haematology-oncology portfolio through Antengene partnership
August 1, 2025 - - Latest News -
AbbVie therapy now available on the PBS for treatment of advanced Parkinson’s
August 1, 2025 - - Latest News